Docoh
Loading...

TARO Taro Pharmaceutical Industries

Filed: 19 May 21, 8:00pm

 

                  

                                                                                                                        

          

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of May, 2021

 

Commission File Number 001-35463

Taro Pharmaceutical Industries Ltd.

(Translation of registrant’s name into English)

 

14 Hakitor Street, Haifa Bay 2624761, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F       Form 40-F  

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

          


 

        

 

FOR IMMEDIATE RELEASE

 

CONTACTS:

Daphne Huang

VP, CFO

(914) 345-9001

Daphne.Huang@taro.com

William J. Coote

AVP, Treasurer and Investor Relations

(914) 345-9001

William.Coote@taro.com

 

TARO PROVIDES RESULTS FOR THE YEAR ENDED MARCH 31, 2021

 

Hawthorne, NY, May 19, 2021 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2021.

 

Quarter ended March 31, 2021 Highlights ─ compared to March 31, 2020

 

Net sales of $148.3 million decreased $26.6 million. The prior year quarter was higher than normal partly due to stocking up by customers as the outbreak of COVID-19 was beginning.

 

Gross profit of $76.9 million (51.9% of net sales compared to 58.5%) decreased $25.3 million.

 

Research and development (R&D) expenses of $16.6 million marginally increased.

 

Selling, marketing, general and administrative expenses (SG&A) of $22.2 million decreased $6.9 million.

 

Settlements and loss contingencies of $80.0 million reflect an additional legal contingency provision related to ongoing multi-jurisdiction civil antitrust matters; however, there can be no assurance as to the ultimate outcome.

 

Operating (loss) of $(41.9) million compared to operating income of $57.2 million.  Excluding the settlement and loss contingencies charges, operating income was $38.1 million, a decrease of $19.1 million, and as a percentage of net sales was 25.7% compared to 32.7%.

 

Interest and other financial income of $3.2 million decreased $3.4 million, reflecting the continuing low global interest rate environment.

 

Foreign Exchange (FX) income of $0.8 million compared to $3.7 million ─ an unfavorable impact of $2.8 million.

 

Tax (benefit) of $(8.9) million compared to tax expense of $13.9 million. Excluding the impact from the settlement and loss contingencies charges, the effective tax rate was 18.5% compared to 20.4%.

 

Net (loss) attributable to Taro was $(29.8) million compared to net income of $54.2 million, resulting in diluted (loss) per share of $(0.78) compared to diluted earnings per share of $1.42. Excluding the impact from the settlement and loss contingencies charges, net income was $31.0 million, resulting in diluted earnings per share of $0.81.

 

Year ended March 31, 2021 Highlights ─ compared to March 31, 2020

 

Net sales of $549.0 million decreased $95.8 million.

 

Gross profit of $296.7 million (54.0% of net sales compared to 62.0%) decreased $103.1 million.

 

R&D expenses of $60.2 million remained in line with the prior year.

 

SG&A of $91.4 million decreased $2.1 million.

 

Settlements and loss contingencies of $558.9 million reflect the one-time settlement charge which consists of $418.9 million related to the global resolution of the Department of Justice (“DOJ”) investigations into the U.S. generic pharmaceutical industry and a $140.0 million provision related to ongoing multi-jurisdiction civil antitrust matters; however, there can be no assurance as to the ultimate outcome.

 

Operating (loss) of $(413.8) million compared to operating income of $246.5 million.  Excluding the settlement and loss contingencies charges, operating income was $145.1 million, a decrease of $101.4 million, and as a percentage of net sales was 26.4% compared to 38.2%.

 

Interest and other financial income decreased $13.5 million to $20.2 million.

 

FX expense of $0.4 million compared to FX income of $14.8 million ─ an unfavorable impact of $15.2 million.

 

Tax expense of $9.7 million decreased $43.8 million from $53.5 million in the prior year. Excluding the impact from the settlement and loss contingencies charges, the effective tax rate was 15.7% compared to 17.9%.

 

Net (loss) attributable to Taro was $(386.7) million compared to net income of $244.2 million, resulting in diluted (loss) per share of $(10.12) compared to diluted earnings per share of $6.35.  Excluding the impact from the settlement and loss contingencies charges, net income was $141.4 million, resulting in diluted earnings per share of $3.70.


Cash Flow and Balance Sheet Highlights

 

Cash flow provided by operations for the year ended March 31, 2021, was $45.8 million. Excluding the impact from the settlement and loss contingencies charges, cash flow provided by operations was $130.3 million compared to $271.6 million for the year ended March 31, 2020.

 

As of March 31, 2021, cash and cash equivalents and marketable securities (both short and long-term) increased $12.5 million to $1.58 billion from March 31, 2020.  Cash and cash equivalents reflects the impact from a $102.8 million payment under the DOJ settlement agreement and share repurchases of $24.2 million.

 

 

Mr. Uday Baldota, Taro’s CEO, stated, “While we are encouraged by the sequential quarter-over-quarter revenue growth and the general trend of revenue this year, we continue to be negatively impacted by the COVID-19 pandemic and the effects it is having on the overall marketplace.  Despite the difficult operating environment, we continue to maintain our leading market share, with 70% of our products ranking in the top two in the U.S. generic market. We continue to concentrate on creating shareholder value by continuing our R&D investment, maintaining a healthy pipeline, a robust, consistent flow of ANDA submissions and approvals from the FDA, and timely and successful launches of our products.”

 

FDA Approvals and Filings

The Company recently received three approvals from the U.S. Food and Drug Administration (“FDA”) for an Abbreviated New Drug Applications (“ANDAs”); Imiquimod Cream USP, 3.75%, Clobetasol Propionate Shampoo, 0.05% and Tavaborole Topical Solution, 5%.  In total, the Company reported eight FDA approvals in the year.  The Company currently has a total of twenty ANDAs awaiting FDA approval, including five tentative approvals.

 

Share Repurchase Program - Returning Capital to Shareholders

 

On November 4, 2019, the Company announced that its Board of Directors approved a share repurchase of ordinary shares up to $300 million.  The repurchase authorization enables the Company to purchase its ordinary shares from time to time through open market purchases (including 10b5-1 trading plans), privately negotiated transactions, tender offer or other means, in accordance with applicable securities laws and other regulations.  No time period has been set for the repurchase program, and any such program may be suspended or discontinued at any time.

 

During the quarter, the Company repurchased 278,705 shares at an average price of $75.98.  In total, through March 31, 2021, the Company has repurchased 332,033 shares at an average price of $75.23.

 

Taro Announces the Launch of New Skincare Brand, Bee Rx™

 

On May 1, 2021, Taro Pharmaceuticals U.S.A., Inc. launched its newest brand in a growing family: Bee Rx™, a new kind of wellness. Bee Rx™ products are manufactured in New Zealand, using a clinically proven, unique combination of medical grade kanuka honey and bee venom.  Bee Rx™ launch product line includes anti-aging serums, lip plumpers, and acne blemish repair. 

 

The Company cautions that the foregoing 2021 financial information is unaudited and is subject to change.  

 

************************



 

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.  For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

 

SAFE HARBOR STATEMENT

The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company.  The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the SEC.

 

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2021.  Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained.  Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F.  Forward-looking statements are applicable only as of the date on which they are made.  The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

 

**Financial Tables Follow**


 

 

TARO PHARMACEUTICAL INDUSTRIES LTD.

SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except share data)

 

 

 

Quarter Ended

 

 

Year Ended

 

 

March 31,

 

 

March 31,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(unaudited)

 

 

(unaudited)

 

 

(unaudited)

 

 

(audited)

 

Sales, net

$

148,348

 

 

$

174,940

 

 

$

548,970

 

 

$

644,769

 

Cost of sales

 

71,414

 

 

 

72,668

 

 

 

252,314

 

 

 

245,044

 

Gross profit

 

76,934

 

 

 

102,272

 

 

 

296,656

 

 

 

399,725

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Research and development

 

16,587

 

 

 

15,799

 

 

 

60,152

 

 

 

59,777

 

   Selling, marketing, general and administrative

 

22,234

 

 

 

29,111

 

 

 

91,355

 

 

 

93,413

 

   Settlements and loss contingencies

 

80,000

 

 

 

150

 

 

 

558,924

 

 

 

 

Operating (loss) income

 

(41,887

)

 

 

57,212

 

 

 

(413,775

)

 

 

246,535

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial (income) expense, net:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Interest and other financial income

 

(3,185

)

 

 

(6,633

)

 

 

(20,174

)

 

 

(33,645

)

  Foreign exchange (income) expense

 

(842

)

 

 

(3,690

)

 

 

365

 

 

 

(14,837

)

Other gain, net

 

100

 

 

 

808

 

 

 

2,892

 

 

 

3,018

 

(Loss) income before income taxes

 

(37,760

)

 

 

68,343

 

 

 

(391,073

)

 

 

298,035

 

Tax (benefit) expense

 

(8,878

)

 

 

13,920

 

 

 

9,667

 

 

 

53,485

 

Net (loss) income

 

(28,882

)

 

 

54,423

 

 

 

(400,740

)

 

 

244,550

 

Net income (loss) attributable to non-controlling interest

 

904

 

 

 

225

 

 

 

(14,087

)

 

 

309

 

Net (loss) income attributable to Taro

$

(29,786

)

 

$

54,198

 

 

$

(386,653

)

 

$

244,241

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per ordinary share attributable to Taro:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

$

(0.78

)

 

$

1.42

 

 

$

(10.12

)

 

$

6.35

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of shares used to compute net income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

 

38,065,388

 

 

 

38,258,337

 

 

 

38,209,726

 

 

 

38,460,056

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

May not foot due to rounding.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

TARO PHARMACEUTICAL INDUSTRIES LTD.

SUMMARY CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

 

March 31,

 

 

March 31,

 

 

2021

 

 

2020

 

ASSETS

(unaudited)

 

 

(audited)

 

CURRENT ASSETS:

 

 

 

 

 

 

 

Cash and cash equivalents

$

605,177

 

 

$

513,354

 

Marketable securities

 

418,480

 

 

 

595,383

 

Accounts receivable and other:

 

 

 

 

 

 

 

   Trade, net

 

213,539

 

 

 

235,221

 

   Other receivables and prepaid expenses

 

53,347

 

 

 

35,567

 

Inventories

 

180,292

 

 

 

153,073

 

TOTAL CURRENT ASSETS

 

1,470,835

 

 

 

1,532,598

 

Marketable securities

 

557,209

 

 

 

459,639

 

Property, plant and equipment, net

 

205,508

 

 

 

209,961

 

Deferred income taxes

 

142,007

 

 

 

106,693

 

Other assets

 

31,314

 

 

 

32,361

 

TOTAL ASSETS

$

2,406,873

 

 

$

2,341,252

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

 

Trade payables

$

61,166

 

 

$

28,858

 

Other current liabilities

 

615,135

 

 

 

193,873

 

TOTAL CURRENT LIABILITIES

 

676,301

 

 

 

222,731

 

Deferred taxes and other long-term liabilities

 

35,115

 

 

 

8,762

 

TOTAL LIABILITIES

 

711,416

 

 

 

231,493

 

 

 

 

 

 

 

 

 

Taro shareholders' equity

 

1,703,649

 

 

 

2,103,864

 

Non-controlling interest

 

(8,192

)

 

 

5,895

 

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$

2,406,873

 

 

$

2,341,252

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

TARO PHARMACEUTICAL INDUSTRIES LTD.

SUMMARY CONSOLIDATED STATEMENT OF CASH FLOWS

(U.S. dollars in thousands)

 

 

 

Year Ended March 31,

 

 

2021

 

 

2020

 

 

(unaudited)

 

 

(audited)

 

Cash flows from operating activities:

 

 

 

 

 

 

 

Net (loss) income

$

(400,740

)

 

$

244,550

 

Adjustments required to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

     Depreciation and amortization

 

23,680

 

 

 

21,383

 

     Realized loss on sale of long-lived assets

 

92

 

 

 

28

 

     Change in derivative instruments, net

 

(236

)

 

 

(2,649

)

     Effect of change in exchange rate on marketable securities and bank deposits

 

(4,588

)

 

 

(11,600

)

     Deferred income taxes, net

 

(38,413

)

 

 

7,584

 

     Decrease in trade receivables, net

 

21,683

 

 

 

2,724

 

     Increase in inventories, net

 

(27,219

)

 

 

(4,994

)

     (Increase) decrease in other receivables, income tax receivables, prepaid expenses and other

 

(16,325

)

 

 

12,137

 

     Increase in trade, income tax, accrued expenses and other payables

 

482,520

 

 

 

782

 

     Loss from marketable securities, net

 

5,316

 

 

 

1,660

 

Net cash provided by operating activities

 

45,770

 

 

 

271,605

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

     Purchase of plant, property & equipment, net

 

(16,983

)

 

 

(26,610

)

     Investment in other intangible assets

 

(161

)

 

 

(1,783

)

     Proceeds from (investment in) marketable securities, net

 

84,885

 

 

 

(269,769

)

Net cash provided by (used in) investing activities

 

67,741

 

 

 

(298,162

)

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

     Purchase of treasury stock

 

(24,196

)

 

 

(26,984

)

Net cash used in financing activities

 

(24,196

)

 

 

(26,984

)

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

2,508

 

 

 

(556

)

Increase (decrease) in cash and cash equivalents

 

91,823

 

 

 

(54,097

)

Cash and cash equivalents at beginning of period

 

513,354

 

 

 

567,451

 

Cash and cash equivalents at end of period

$

605,177

 

 

$

513,354

 

 

 

 

 

 

 

 

 

Cash Paid during the year for:

 

 

 

 

 

 

 

Income taxes

$

29,377

 

 

$

54,536

 

Cash Received during the year for:

 

 

 

 

 

 

 

Income taxes

$

4,093

 

 

$

24,331

 

Non-cash investing transactions:

 

 

 

 

 

 

 

Purchase of property, plant and equipment included in accounts payable

$

2,997

 

 

$

1,477

 

Non-cash financing transactions:

 

 

 

 

 

 

 

Purchase of intangible assets

$

15

 

 

$

 

Purchase of treasury stock

$

782

 

 

$

 

Purchase of marketable securities

$

9,417

 

 

$

9,159

 

 

 

 

 

 

 

 

 

#####


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:  May 19, 2021

TARO PHARMACEUTICAL INDUSTRIES LTD.

By:  /s/ Uday Baldota

Name:Uday Baldota

Title:Chief Executive Officer and Director